Renal clearable sucrose carbon dots for doxorubicin delivery to treat renal carcinoma.
Farhana Azmi, Xiaoxue Xu, Hien Duong, Ping Ye, Titi Chen, Hongxi Li, Jianwei Chen, Sara Madadi Ardekani, Alireza Dehghani, Guoping Zheng, David Harris, Hongxu Lu, Yiping Wang, Qi Cao
Author Information
Farhana Azmi: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au. ORCID
Xiaoxue Xu: Institute for Biomedical Materials and Devices, University of Technology Sydney Australia. ORCID
Hien Duong: Faculty of Medicine and Health, The University of Sydney NSW Australia. ORCID
Ping Ye: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Titi Chen: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Hongxi Li: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Jianwei Chen: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Sara Madadi Ardekani: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Alireza Dehghani: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Guoping Zheng: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
David Harris: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Hongxu Lu: Institute for Biomedical Materials and Devices, University of Technology Sydney Australia.
Yiping Wang: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Qi Cao: Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, The University of Sydney NSW Australia fazm3421@uni.sydney.edu.au farah.s.azmi@gmail.com qi.cao@sydney.edu.au.
Renal Cell Carcinoma (RCC) poses challenges for conventional treatment methods, but recent advancements indicate the potential of nanoparticles (NPs) in enhancing chemotherapy efficacy. This study focuses on developing non-toxic NPs from sucrose and l-serine hydrothermal synthesis to produce Sucrose Carbon Dots (Suc CDs), designed for renal clearance to deliver hydrophilic drugs for the treatment of RCC. Suc CDs with a size of 4 nm exhibit high fluorescence with a fluorescence quantum yield of 58% and high drug loading capacity without toxicity to normal cell lines (renal tubular cells). Under conditions, Suc CDs alone are non-toxic, while Suc CDs with DOX display improved anticancer effects on Renca cells (cancer cell line). Under conditions, Suc CDs loaded with DOX outperform DOX alone with reduced toxicity to normal cells. Biodistribution study of Suc CDs revealed prolonged tumour site accumulation. This research demonstrates that renal clearable Suc CDs loaded with DOX exhibit superior anti-cancer activity, and are free of side effects, suggesting promising therapeutic potential for human RCC.
